Aducanumab: a new drug for Alzheimer's disease
- US Food and Drug Administration has approved Biogen’s Aducanumab (Aduhelm), the first drug to target an underlying cause of Alzheimer’s disease.
- There are 30 million people suffering from Alzheimer's disease globally. Of them, about 6 million are in the US,
- Alzheimer's disease is the most common form of dementia and contributes 60-70 percent of the cases.
- The Drug was Tested on patients who were in the early stage of Alzheimer’s disease, not on moderate or severe cases.
How it works:
- Aduhelm, is a monoclonal (referring to cloning of unique immunity cell) antibody that reduces amyloid-beta, which is a protein that leads to plaque formation in the brain.
- Plaque formation happens due to the accumulation of debris in the brain from neuron breakdown.
- The drug slow the progression of Alzheimer’s disease, allowing patients to remain as self-sufficient as possible for as long as possible.
- It is not a cure.
- Brain swelling, due to high dose
- Cost: about $56,000 per year
What is Alzheimer’s disease
- Alzheimer's is the most common cause of dementia, a general term for memory loss and other cognitive abilities serious enough to interfere with daily life.
- Alzheimer's disease accounts for 60-80% of dementia cases.
- According to the World Health Organisation (WHO), it is a syndrome in which there is deterioration in memory, thinking, behaviour and the ability to perform everyday activities